Bionano Genomics, Inc

www.bionanogenomics.com

At Bionano Genomics®, we are committed to unlocking understanding of genome biology to advance the promise of genomics in areas including cancer and human disease, agricultural bioengineering and genome discovery. Our team is not afraid to venture into uncharted territory to look for answers. We welcome the curious and provide a place where those who are not satisfied with the status quo can feel at home.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Industrial Impact, Medical

GUARDANT HEALTH ANNOUNCES NEW DATA TO BE PRESENTED AT 2023 DIGESTIVE DISEASE WEEK SHOWCASING THE POTENTIAL OF ITS BLOOD-BASED TECHNOLOGY

Businesswire | April 24, 2023

news image

Guardant Health, Inc. a leading precision oncology company, is pleased to announce that it will present data from two studies highlighting the performance of its blood-based screening technology to detect early-stage colorectal cancer (CRC), including the acceptance of the ECLIPSE study as a late-breaking abstract, at Digestive Disease Week (DDW) taking place in Chicago, Illinois on May 6-9, 2023. “Despite multiple screening modalities for colorectal cancer, screening rate...

Read More

CORONAVIRUS VACCINES ARE MOVING TOWARDS CLINICAL TRIALS, PROMISES SEVERAL BIOTECH COMPANIES IN THE US

Edex Live | April 09, 2020

news image

Just three months after the outbreak of the coronavirus pandemic, several biotech companies in the United States have ramped up their efforts to fight the disease with accelerated schedules for creating new vaccines and beginning clinical trials for potential treatments. In normal circumstances, vaccine development would take around 10 years. But the pharmaceutical industry is racing to compress this timeline with the support of non-profit organisations, government agencies and regulatory author...

Read More

US BIOTECH FIRM DONATING 1.5 MILLION DOSES OF EXPERIMENTAL CORONAVIRUS DRUG

TheHill | April 05, 2020

news image

Gilead Sciences Inc., a U.S. biotechnology firm that develops and commercializes drugs, has rapidly expanded its supply of an experimental coronavirus drug and is prepared to donate 1.5 million doses of it to hospitals dealing with severely ill patients. Gilead CEO Daniel O'Day said in a statement Saturday that the 1.5 million doses of the drug, known as remdesivir, could be part of treatment courses for as many as 140,000 patients. He said the doses were available for "compassionate us...

Read More

Industrial Impact

HOW MIGHT BIOMOLECULAR CONDENSATES REVOLUTIONIZE DRUG DISCOVERY? A PERSPECTIVE FROM DEWPOINT THERAPEUTICS

Dewpoint Therapeutics | August 18, 2022

news image

A new perspective published in Nature Reviews Drug Discovery examines the potential of biomolecular condensates to transform drug discovery. Condensates are membrane-less organelles that form dynamically throughout the cell via a process called phase separation. Over the last decade scientists have recognized the role of biomolecular condensates in cellular organization and disease, marking one of the most revolutionary areas of biology. In "Modulating biomolecular condensate...

Read More
news image

Industrial Impact, Medical

GUARDANT HEALTH ANNOUNCES NEW DATA TO BE PRESENTED AT 2023 DIGESTIVE DISEASE WEEK SHOWCASING THE POTENTIAL OF ITS BLOOD-BASED TECHNOLOGY

Businesswire | April 24, 2023

Guardant Health, Inc. a leading precision oncology company, is pleased to announce that it will present data from two studies highlighting the performance of its blood-based screening technology to detect early-stage colorectal cancer (CRC), including the acceptance of the ECLIPSE study as a late-breaking abstract, at Digestive Disease Week (DDW) taking place in Chicago, Illinois on May 6-9, 2023. “Despite multiple screening modalities for colorectal cancer, screening rate...

Read More
news image

CORONAVIRUS VACCINES ARE MOVING TOWARDS CLINICAL TRIALS, PROMISES SEVERAL BIOTECH COMPANIES IN THE US

Edex Live | April 09, 2020

Just three months after the outbreak of the coronavirus pandemic, several biotech companies in the United States have ramped up their efforts to fight the disease with accelerated schedules for creating new vaccines and beginning clinical trials for potential treatments. In normal circumstances, vaccine development would take around 10 years. But the pharmaceutical industry is racing to compress this timeline with the support of non-profit organisations, government agencies and regulatory author...

Read More
news image

US BIOTECH FIRM DONATING 1.5 MILLION DOSES OF EXPERIMENTAL CORONAVIRUS DRUG

TheHill | April 05, 2020

Gilead Sciences Inc., a U.S. biotechnology firm that develops and commercializes drugs, has rapidly expanded its supply of an experimental coronavirus drug and is prepared to donate 1.5 million doses of it to hospitals dealing with severely ill patients. Gilead CEO Daniel O'Day said in a statement Saturday that the 1.5 million doses of the drug, known as remdesivir, could be part of treatment courses for as many as 140,000 patients. He said the doses were available for "compassionate us...

Read More
news image

Industrial Impact

HOW MIGHT BIOMOLECULAR CONDENSATES REVOLUTIONIZE DRUG DISCOVERY? A PERSPECTIVE FROM DEWPOINT THERAPEUTICS

Dewpoint Therapeutics | August 18, 2022

A new perspective published in Nature Reviews Drug Discovery examines the potential of biomolecular condensates to transform drug discovery. Condensates are membrane-less organelles that form dynamically throughout the cell via a process called phase separation. Over the last decade scientists have recognized the role of biomolecular condensates in cellular organization and disease, marking one of the most revolutionary areas of biology. In "Modulating biomolecular condensate...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us